Clinical tests begin for German-U.S. coronavirus vaccine
A GERMAN-U.S. coronavirus vaccine has been administered to human test subjects in the U.S., the companies involved reported on Tuesday.
After preliminary tests in Germany, Biontech of Mainz and U.S.-based Pfizer are advancing the clinical trial of BNT162, an mRNA vaccine, in the U.S.
The next round of tests in Germany will involve 200 healthy volunteers age 18 to 55, overseen by Paul Ehrlich Institute, Germany’s federal institute for vaccines.
The first results should be available in June.
If initial tests show a positive result, the tests will continue with more healthy participants as well as high-risk people.
THE NATION
Please, remember to always like our page and visit our website for updates. You can also download our android mobile app from google playstore
